1. Home
  2. Analysis
  3. Solu-medrol
  4. Rebif

Solu-medrol vs. Rebif: side effect and effectiveness comparison (a real world drug study)

Summary:

We compare the side effects and drug effectiveness of Solu-medrol and Rebif. The phase IV clinical study is created by eHealthMe based on reports (from sources including the FDA) of 182,548 people who take Solu-medrol and Rebif, and is updated regularly.

What is Solu-medrol?

Solu-medrol has active ingredients of methylprednisolone sodium succinate. It is often used in multiple sclerosis. eHealthMe is studying from 39,410 Solu-medrol users. Check the latest studies of Solu-medrol.

What is Rebif?

Rebif has active ingredients of interferon beta-1a. It is often used in multiple sclerosis. eHealthMe is studying from 61,126 Rebif users. Check the latest studies of Rebif.

On Jul, 15, 2026

182,548 people who take Solu-medrol and Rebif are studied.

Solu-medrol vs Rebif drug comparison reports.

Drugs being compared in this study:

  • Rebif (interferon beta-1a)
  • Solu-Medrol (methylprednisolone sodium succinate)

Most common side effects of the drugs, overall:

Click here to view

Most common side effects of the drugs, in long term (1+ years) use:

Click here to view

Drug effectiveness:

Solu-Medrol:

  • not at all: 14.93 %
  • somewhat: 28.36 %
  • moderate: 20.9 %
  • high: 31.34 %
  • very high: 4.48 %

Rebif:

  • not at all: 7.69 %
  • somewhat: 12.09 %
  • moderate: 28.57 %
  • high: 40.66 %
  • very high: 10.99 %

Want to compare Solu-medrol with Rebif?

- Personalize this study to your gender and age (0-99+)

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Related studies

Alternative drugs to, pros and cons of:

Browse all side effects of Solu-medrol:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Rebif:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study is based on methylprednisolone sodium succinate and interferon beta-1a (the active ingredients of Solu-medrol and Rebif, respectively). Other drugs that have the same active ingredients (e.g. generic drugs or brand names) are also considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.